SCHEMBL6947618

SCHEMBL6947618

Cc1nc(N2CCc3ccccc3CC2)c([N+](=O)[O-])c(=O)n1CC(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.37
CYP2D6 P10635 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 2/20 0.37
CNR1 P21554 1/20 0.37
MAPT P10636 5/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.34
HTT P42858 1/20 0.34
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6946348 0.87 MAPT (0.42) CYP2C9CYP2D6MEN1KMT2APOLB
SCHEMBL6952859 0.86 CYP2C9 (0.40) CYP2C9CYP2D6MEN1KMT2APOLB
SCHEMBL6952584 0.85 CYP2C9 (0.40) CYP2C9CYP2D6MEN1KMT2APOLB
SCHEMBL4422914 0.85 MAPT (0.43) CYP2C9CYP2D6MAPTCYP1A2CYP3A4
SCHEMBL6953752 0.84 CYP2C9 (0.40) CYP2C9CYP2D6MEN1KMT2APOLB
SCHEMBL6952446 0.84 CYP2C9 (0.38) CYP2C9CYP2D6MEN1KMT2APOLB
SCHEMBL6952822 0.83 CYP2C9 (0.39) CYP2C9CYP2D6MEN1KMT2APOLB
SCHEMBL6950082 0.82 ALDH1A1 (0.39) CYP2C9CYP2D6MEN1KMT2APOLB
SCHEMBL6949240 0.82 TSHR (0.46) CYP2C9CYP2D6MEN1KMT2APOLB
SCHEMBL4414941 0.82 POLB (0.44) CYP2C9MEN1KMT2APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP claimed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US claimed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP claimed
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed